These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 16180116

  • 1. Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs.
    Leon C, Hill JS, Wasan KM.
    Pharm Res; 2005 Oct; 22(10):1578-88. PubMed ID: 16180116
    [Abstract] [Full Text] [Related]

  • 2. Acyl coenzyme A:cholesterol acyltransferase inhibitors as hypolipidemic and antiatherosclerotic drugs.
    Alegret M, Llaverias G, Silvestre JS.
    Methods Find Exp Clin Pharmacol; 2004 Sep; 26(7):563-86. PubMed ID: 15538545
    [Abstract] [Full Text] [Related]

  • 3. Human acyl-CoA:cholesterol acyltransferase (ACAT) and its potential as a target for pharmaceutical intervention against atherosclerosis.
    Chang C, Dong R, Miyazaki A, Sakashita N, Zhang Y, Liu J, Guo M, Li BL, Chang TY.
    Acta Biochim Biophys Sin (Shanghai); 2006 Mar; 38(3):151-6. PubMed ID: 16518538
    [Abstract] [Full Text] [Related]

  • 4. Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis.
    Miyazaki A, Sakai M, Sakamoto Y, Horiuchi S.
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1095-9. PubMed ID: 14582454
    [Abstract] [Full Text] [Related]

  • 5. Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion.
    Burnett JR, Wilcox LJ, Huff MW.
    Clin Chim Acta; 1999 Aug; 286(1-2):231-42. PubMed ID: 10511295
    [Abstract] [Full Text] [Related]

  • 6. Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2.
    Chang TY, Chang CC, Lin S, Yu C, Li BL, Miyazaki A.
    Curr Opin Lipidol; 2001 Jun; 12(3):289-96. PubMed ID: 11353332
    [Abstract] [Full Text] [Related]

  • 7. Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.
    Miyazaki A, Kanome T, Watanabe T.
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):463-9. PubMed ID: 16503866
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): could it be a new antiatherosclerotic therapeutic?
    López-Farré AJ, Sacristán D, Zamorano-León JJ, San-Martín N, Macaya C.
    Cardiovasc Ther; 2008 Dec; 26(1):65-74. PubMed ID: 18466422
    [Abstract] [Full Text] [Related]

  • 9. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice.
    Kusunoki J, Hansoty DK, Aragane K, Fallon JT, Badimon JJ, Fisher EA.
    Circulation; 2001 May 29; 103(21):2604-9. PubMed ID: 11382731
    [Abstract] [Full Text] [Related]

  • 10. Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: individual ACAT uniqueness.
    Lada AT, Davis M, Kent C, Chapman J, Tomoda H, Omura S, Rudel LL.
    J Lipid Res; 2004 Feb 29; 45(2):378-86. PubMed ID: 14617738
    [Abstract] [Full Text] [Related]

  • 11. Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis.
    Rudel LL, Lee RG, Cockman TL.
    Curr Opin Lipidol; 2001 Apr 29; 12(2):121-7. PubMed ID: 11264983
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.
    Junquero D, Oms P, Carilla-Durand E, Autin J, Tarayre J, Degryse A, Patoiseau J, Colpaert FC, Delhon A.
    Biochem Pharmacol; 2001 Jan 01; 61(1):97-108. PubMed ID: 11137714
    [Abstract] [Full Text] [Related]

  • 13. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels.
    Ikenoya M, Yoshinaka Y, Kobayashi H, Kawamine K, Shibuya K, Sato F, Sawanobori K, Watanabe T, Miyazaki A.
    Atherosclerosis; 2007 Apr 01; 191(2):290-7. PubMed ID: 16820149
    [Abstract] [Full Text] [Related]

  • 14. Acyl coenzyme A:cholesterol acyltransferase inhibition: potential atherosclerosis therapy or springboard for other discoveries?
    Heinonen TM.
    Expert Opin Investig Drugs; 2002 Nov 01; 11(11):1519-27. PubMed ID: 12437499
    [Abstract] [Full Text] [Related]

  • 15. Discovery and combinatorial synthesis of fungal metabolites beauveriolides, novel antiatherosclerotic agents.
    Tomoda H, Doi T.
    Acc Chem Res; 2008 Jan 01; 41(1):32-9. PubMed ID: 17803269
    [Abstract] [Full Text] [Related]

  • 16. Impaired mobilisation of cholesterol from stored cholesteryl esters in human (THP-1) macrophages.
    Graham A, Angell AD, Jepson CA, Yeaman SJ, Hassall DG.
    Atherosclerosis; 1996 Feb 01; 120(1-2):135-45. PubMed ID: 8645354
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of acyl-CoA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells.
    Musanti R, Giorgini L, Lovisolo PP, Pirillo A, Chiari A, Ghiselli G.
    J Lipid Res; 1996 Jan 01; 37(1):1-14. PubMed ID: 8820097
    [Abstract] [Full Text] [Related]

  • 18. Liver-specific inhibition of acyl-coenzyme a:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice.
    Bell TA, Brown JM, Graham MJ, Lemonidis KM, Crooke RM, Rudel LL.
    Arterioscler Thromb Vasc Biol; 2006 Aug 01; 26(8):1814-20. PubMed ID: 16675724
    [Abstract] [Full Text] [Related]

  • 19. Compared with Acyl-CoA:cholesterol O-acyltransferase (ACAT) 1 and lecithin:cholesterol acyltransferase, ACAT2 displays the greatest capacity to differentiate cholesterol from sitosterol.
    Temel RE, Gebre AK, Parks JS, Rudel LL.
    J Biol Chem; 2003 Nov 28; 278(48):47594-601. PubMed ID: 12975367
    [Abstract] [Full Text] [Related]

  • 20. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND, Liang KH.
    Circulation; 2004 Jul 27; 110(4):419-25. PubMed ID: 15262831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.